肉瘤样肾细胞癌的系统治疗。

Systemic therapy for sarcomatoid renal cell carcinoma.

机构信息

Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

出版信息

Expert Rev Anticancer Ther. 2011 Jun;11(6):913-20. doi: 10.1586/era.11.39.

DOI:10.1586/era.11.39

PMID:21707288

Abstract

Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

摘要

肾细胞癌（RCC）是最常见的肾脏恶性肿瘤，而肉瘤样 RCC 是一种侵袭性和致命性的变体。肉瘤样特征可见于所有类型的 RCC 中，并不构成单独的组织学类型。尚未发现肉瘤样变体的任何细胞或遗传生物标志物。大多数为转移性 RCC 开发的系统治疗方法在肉瘤样 RCC 中的效果较差，尽管一些细胞毒性药物实际上可能对肉瘤样 RCC 更有效，因为其增殖速度较快。目前正在进行几项前瞻性临床试验，以研究用于治疗这种疾病的新药物组合。